Novel Oral Drugs to Control Various Inflammatory Conditions
Novel Oral Drugs to Control Various Inflammatory Conditions
OmegaOne Therapeutics - Inhibiting the NLRP3 Inflammasome for Treatment of Sepsis
Tags: Monash University, Australia, Healthcare & Lifesciences
Omega One Therapeutics is advancing a new class of orally administered small molecule inhibitors targeting GSTO1 to control inflammatory diseases. These inhibitors prevent the formation of the NLRP3 inflammasome, implicated in various conditions including cardiovascular and Parkinson’s disease. With unique tools and knowledge of GST proteins, they are optimizing leads to inhibit IL-1β release, a pro-inflammatory cytokine. This novel approach has no known competitors, offering a promising alternative for inflammasome inhibition. The team is seeking investment to progress towards in vivo proof-of-concept studies.
IP Type or Form Factor: Patent Pending; Process & Method; Platform
TRL: 2 - technology concept and/or application formulated
Industry or Tech Area: Biotechnology; Pharmaceutical Engineering
